As we know, when PD-1 and PD-L1 are bound, T cell activity is inhibited, and these drugs exert their functional activity by blocking the binding of PD-1 to PD-L1, thus triggering T cells to re-recognize and attack tumor cells (13). This evidence concerns the gene CD274 and neoplasm.